Whereas the luminal A and B subtypes are characterized by their epithelial phenotypes, hormone sensitivity (estrogen receptor positive, ER+/ progesterone receptor positive, PR+), mildly invasive capacity and relatively good clinical outcome, the HER2+ and basal-like breast cancer (BLBC) subtypes are characterized by their mesenchymal phenotype, insensitivity to hormonal therapy (ER-ve; PR-ve), enhanced invasiveness and metastatic capacity [2] and poor clinical outcome [3-7]. The gene discussed is ERBB2; the disease is breast carcinoma.